Results from a randomized phase ½ trial evaluating the safety and antitumor activity of anti-PD-1 (MEDI0680)/anti-PD-L1 (durvalumab) vs anti-PD-1 (nivolumab) alone in metastatic clear cell renal cell carcinoma - Voss, MH (2019)
Posterpräsentation